CD8A and neoplasm: A recent study demonstrated that vaccination of mice with AAV6 designed to express tumor-associated antigens (TAAs) in dendritic cells (DCs) could increase cytotoxic T cells’ (CTLs’), CD8+ T cells’, and NK cells’ infiltration into the tumor microenvironment, leading to antigen-specific antibody production, the complement-dependent killing of melanoma cells, and protection of mice against tumor nodules in the lungs, highlighting the efficacy of the rAAV-based vaccines [22].